Search Results

tVNS Turkiye Team Our team Selin Erdogan Gezen Selin Erdogan Gezen was born in 1980 in Izmir. She graduated from Middle East Technical University, Department of Industrial Engineering in 2002. She started her career at Vestel Electronics. She continued her career as project manager at Arkas Holding and Greencat Rotterdam. She had various positions as business development project manager at Vodafone Turkey, and Internet and Mobile Vice President at Garanti BBVA Bank. She worked as a senior program manager in innovative technology projects in Turkey, United Kingdom and Germany in the enterprise software unit of Hewlett Packard. She started working on neuromodulation technologies as a founding partner of Nervovita Medical Technologies, in 2019. She made transcutaneous vagal nerve stimulation to become an accessible treatment in Turkey. As of January 2022, she is the director of global marketing and operations of Germany-based tVNS® Health Gmbh, and supports clinical studies in different diseases with leading universities and institutes in more than 40 countries around the world. Particularly in pediatric neurology, she played an active role in determining the global protocols of therapy by pioneering successful treatments with her studies with physicians from various countries around the world. Kurtulus Berkay Gezen Berkay Gezen was born in Aydın in 1973. He completed the Department of Electrical and Electronics Engineering at Middle East Technical University in 1995. He took part in various international product development projects for 6 years in product management at Beko Electronics . From 2001 to 2007, he continued to work in international trade activities on consumer electronics. Between 2008 and 2018, he served as the global commercial director of CardiAid, the world's leading automatic defibrillator brand for 11 years, from the design of the brand to its spread in over 65 countries of the world. As of 2019, he provides strategic consultancy services to medical technology start-up companies in Turkey and India with his global experience in his field. He joined the founding team of tVNS Technologies in 2018 as global sales director. As of December 2022, he continues to work as the CEO of Germany-based tVNS Health GmbH, which was established to manage the sales and operations of tVNS® devices all over the world, and continues to invest in medical technology to make vagus neuromodulation treatments accessible all over the world. Senem Erdoğan Atay Senem Erdogan Atay was born in Izmir in 1982. Sh e graduated from Middle East Technical University, Department of Chemical Engineering in 2005. She started her career as North America Operations Officer at Maersk Shipping and continued as Product Manager at Deva İlaç. She worked as Project Engineer at Bekaert, Product Manager of Boston Scientific Pacemakers, and Customer Services Team Manager at Eczacıbaşı Building Products Group. She continued her career as Sales Manager at Enelsan. She joined Nervovita Medical Technologies team as Marketing Manager in 2021 and contributed to making tVNS treatment an accessible and widespread treatment in Turkey. As of July 2022, she continues her career as the manager of tVNS Health GmbH responsible for regulations and clinical studies, and manages global medical approval projects with her India-based clinical team. Oguz Can Ergin After completing his undergraduate education in Biomedical Engineering at Yeditepe University, he completed her master's degree in the same department. Since May 2024, he has been working on medical device technology, neuromodulation clinical research, international and patient device education and support in Türkiye. He speaks English fluently. Eylül Doğa Hallac She completed her associate degree in Audiometry at Şişli University. Since July 2024, she has been working on neuromodulation devices, university and hospital studies, device operations and Türkiye patient device training and support. Ahmed Alsharif He completed his undergraduate education in Ankara University Biomedical Engineering Department. Since June 2024, he has been working in medical device technology, neuromodulation devices, neuromodulation clinical research, international and Turkish patient device education and support. He speaks English and Arabic fluently. Aylin Kesat She completed his undergraduate education in Ankara University Biomedical Engineering Department. Since June 2024, she has been working in medical device technology, neuromodulation devices, neuromodulation clinical research, international and Turkish patient device education and support. She speaks English and Arabic fluently. Mariam Ismaeil She completed his undergraduate education in Ankara University Biomedical Engineering Department. Since June 2024, she has been working in medical device technology, neuromodulation devices, neuromodulation clinical research, international and Turkish patient device education and support. She speaks English and Arabic fluently. Merve Nur Akay She completed his undergraduate education in Ankara University Biomedical Engineering Department. Since June 2024, she has been working in medical device technology, neuromodulation devices, neuromodulation clinical research, international and Turkish patient device education and support. He speaks English and Arabic fluently.

tVNS Transkutanöz Vagus Sinir Stimülasyonu cihazıdır. Dirençli Epilepsi, Migren ve Depresyon Tedavisinde Ameliyatsız İlaçsız Kulaktan Vagus Sinirini Uyaran Dünyanın CE onaylı Tek Nöroterapi - vagus stimulasyonu- cihazıdır. tVNS Türkiye , "t-vnstherapy "tek yetkili satıcısıdır. The World Has Evolved, and So Have Therapies The World’s Only Medically Approved, Non-Surgical Vagus Nerve Therapy Registered in the Turkish Ministry of Health’s Product Tracking System (UTS) With 20 Years of Vagus Nerve Therapy Experience in Over 50 Countries, We Are Here to Help You Rediscover Quality of Life. tVNS® Patient Portal Healthcare Professionals To play, press and hold the enter key. To stop, release the enter key. Trusted Globally by Leading Institutions Trusted Innovation in Non-Invasive Neurological Treatment: tVNS® tVNS®, developed in Germany since 2003, is the first and only medically approved device in the world for non-invasive vagus nerve stimulation applied through the ear. tVNS®, which has the European Union CE-MDR Class IIa certification and the approval of the Ministry of Health of the Republic of Türkiye, is used safely by thousands of patients in more than 50 countries. Safe and Effective Approach to Treatment: Application that does not require surgical intervention Clinical efficacy supported by scientific studies Personalized protocols targeting sympathovagal balance Low side effect profile, high patient compliance tVNS® offers a modern and reliable solution for the management of neurological diseases. It has clinical and regulatory approvals for the restoration of sympathovagal balance in the following indications: Anxiety Migraine Autism Cognitive Impairment Depression Fibromyalgia E p ilepsy Inflammation Pr ader-Willi Syndrome Sleep Disorders Tinnitus Asthma Crohn's Disease Atrial Fibrillation Parkinson's Media Coverage of tVNS® To play, press and hold the enter key. To stop, release the enter key. Treatment Stories of tVNS® Patients My 7-year-old son with Dravet syndrome had seizure periods that required intensive care treatments every month. We have been using tVNS for 2 years, and we are happy to have a seizure-free life, obtain mental development, and reduction in autism symptoms. Zeliha KORKMAZ, Kayseri, Erciyes University Prof. Dr. Hakan GÜMÜŞ Get the tVNS® Patient App The tVNS® Patient app communicates with your tVNS® device using Bluetooth. This app allows you to keep an online diary of important health data (your patient's general mood and comfort, seizures if you have epilepsy, and important notes), compile your therapy history recorded on your device into a report, and share all records with your doctor with a single click. It allows you to monitor and make changes to your therapy from the comfort of your home, wherever you are in the world. tVNS® uses an ear electrode to deliver mild electrical impulses (neurostimulation) to the ear, activating specific nerve fibers and stimulating the auricular branch of the vagus nerve through the skin, sending nerve signals to the brainstem and higher centers. This alleviates symptoms of sympathovagal imbalance, such as reducing seizures in epilepsy. How tVNS® Works tVNS® CARE Therapy Tracking THE MOST EFFECTIVE WAY TO GET RESULTS FROM tVNS® In medical device treatments that can be applied at home without a doctor's supervision, the most important requirement for the success of the treatment is that a protocol specific to the patient's needs is prepared and that the patient is using the device correctly and is monitored by the doctor and a team of experts. The world-unique tVNS Care® Technology is a digital health service that can increase the success rate of treatment by up to 50%, where a patient-specific program is prepared by referencing the protocols of similar patients in more than 50 countries, and all details of the treatment can be monitored online by our expert teams. News from tVNS No posts published in this language yet Once posts are published, you’ll see them here. REFERENCES Contact us Name Surname Where did you hear about us? * Internet search tVNS social media (Facebook, instagram) My Follow-Up Doctor Others Which topic do you need to be informed? * Epilepsy Migraine Depression Research Device Your E-mail Address Phone Number Patient's diagnosis history (Diagnostic, medications, follow-up doctor...etc.) Submit Thank you for your interest in tVNS Turkey. We will respond to you as soon as possible. Contact us

tVNS E - İlaca Dirençli Epilepsi için Ameliyatsız Tedavi. İlacın yeterli olmadığı durumlarda vagus sinir stimulasyonu tVNS E, dirençli epilepsi ve major depresyon tedavisinde kullanılan dünyanın tek onaylı non-invazif vagus terapi cihazıdır MIGRAINE What is Migraine? It is a neurological disorder that causes a throbbing, severe headache, often felt intensely on one side of the head. The distinctive features of migraine that distinguish it from other headaches include nausea and vomiting, and sensitivity to sound and light. The pain is so severe that it interferes with the completion of daily activities and leads to limitation. Migraine attacks take the first place among the most important causes of disability and loss of work in developed countries. Many migraine attacks are seen as a type of "migraine without aura". Other conditions accompanying the headache of migraine patients without aura; nausea, vomiting, sensitivity to light, sound and smell. Migraine patients with aura, on the other hand, may experience "aura" attacks ranging from 5 minutes to 60 minutes before the headache attacks begin. What is Migraine? It is a neurological disorder that causes a throbbing, severe headache, often felt intensely on one side of the head. The distinctive features of migraine that distinguish it from other headaches include nausea and vomiting, and sensitivity to sound and light. The pain is so severe that it interferes with the completion of daily activities and leads to limitation. Migraine attacks take the first place among the most important causes of disability and loss of work in developed countries. Many migraine attacks are seen as a type of "migraine without aura". Other conditions accompanying the headache of migraine patients without aura; nausea, vomiting, sensitivity to light, sound and smell. Migraine patients with aura, on the other hand, may experience "aura" attacks ranging from 5 minutes to 60 minutes before the headache attacks begin. Migraine is a genetically inherited disease. In other words, migraine is more common in people with a family history of migraine. Although not in the family, women are at risk for migraine headaches during hormonal transition (adolescence, premenstrual days, menopause) and during the periods when they use birth control pills. . The sensory nerve of our face, cerebral vessels and cerebral cortex is the same. This nerve can also be stimulated in external environment triggers and trigger pain mechanisms in the brain. During migraine, the cerebral vessels first narrow and then expand. The increase in pressure due to enlargement in the brain vessels is the cause of the throbbing finding in the person. Migraine is a genetically inherited disease. In other words, migraine is more common in people with a family history of migraine. Although not in the family, women are at risk for migraine headaches during hormonal transition (adolescence, premenstrual days, menopause) and during the periods when they use birth control pills. . The sensory nerve of our face, cerebral vessels and cerebral cortex is the same. This nerve can also be stimulated in external environment triggers and trigger pain mechanisms in the brain. During migraine, the cerebral vessels first narrow and then expand. The increase in pressure due to enlargement in the brain vessels is the cause of the throbbing finding in the person. Migraine is a genetically inherited disease. In other words, migraine is more common in people with a family history of migraine. Although not in the family, women are at risk for migraine headaches during hormonal transition (adolescence, premenstrual days, menopause) and during the periods when they use birth control pills. . The sensory nerve of our face, cerebral vessels and cerebral cortex is the same. This nerve can also be stimulated in external environment triggers and trigger pain mechanisms in the brain. During migraine, the cerebral vessels first narrow and then expand. The increase in pressure due to enlargement in the brain vessels is the cause of the throbbing finding in the person. Migraine is a genetically inherited disease. In other words, migraine is more common in people with a family history of migraine. Although not in the family, women are at risk for migraine headaches during hormonal transition (adolescence, premenstrual days, menopause) and during the periods when they use birth control pills. . The sensory nerve of our face, cerebral vessels and cerebral cortex is the same. This nerve can also be stimulated in external environment triggers and trigger pain mechanisms in the brain. During migraine, the cerebral vessels first narrow and then expand. The increase in pressure due to enlargement in the brain vessels is the cause of the throbbing finding in the person. Migraine is a genetically inherited disease. In other words, migraine is more common in people with a family history of migraine. Although not in the family, women are at risk for migraine headaches during hormonal transition (adolescence, premenstrual days, menopause) and during the periods when they use birth control pills. . The sensory nerve of our face, cerebral vessels and cerebral cortex is the same. This nerve can also be stimulated in external environment triggers and trigger pain mechanisms in the brain. During migraine, the cerebral vessels first narrow and then expand. The increase in pressure due to enlargement in the brain vessels is the cause of the throbbing finding in the person. Benefits of tVNS® in Migraine Treatment Decrease in the frequency of migraine attacks Reduction of stress-induced migraine triggers Decrease in duration and severity of attacks Decreased need for medication Better quality of life between attacks In a 2015 study, Straube et al. investigated the effectiveness of auricular vagus nerve stimulation (VNS) in migraine prophylaxis. Patients received low-frequency electrical stimulation four times a week, each lasting one hour. A total of 46 patients with chronic migraine participated in this randomized, double-blind, sham-controlled study. Participants were assigned to either the active vagus nerve stimulation or sham stimulation groups. At the end of the four-week treatment period, a significant reduction in migraine days was observed in the active stimulation group, and this effect was more pronounced than in the sham group. Differences in pain intensity and medication use were also found in favor of the active treatment. The study demonstrated that auricular vagus nerve stimulation may be an effective and well-tolerated approach for chronic migraine prophylaxis. Application, Security and Approval Process Minimal Side effect The device is applied through the ear, does not require surgery and has minimal side effects. Possibility of Application at Home It can be easily used by the patient on a daily basis in his or her own home environment. Approved and Safe Approved as a Class IIa medical device under the European Union MDR 2017/745 Complementary to Drug Therapy It can be used alongside drug therapy; there is no need to interrupt treatment. Personalized Therapy Stimulation parameters can be adjusted individually to the patient. WE DESIGN THE MEDICAL TECHNOLOGIES OF THE FUTURE Contact us Contact us

tVNS PARKINSON EXPERIENCE Barry Hanner is a famous Baritone opera singer. He has been using the tVNS device for Parkinson's disease for about two years. Before tVNS, he was suffering from disturbance of equilibrium. He uses it four hours a day at least five times a week. He says that the biggest effect of tVNS is eliminating the disturbance of equilibrium. " tVNS was recommended to help me with my Parkinson's disease symptoms. I use it at least 5 times a week. I realized that the tVNS device has eliminated the balance disorder caused by Parkinson's disease.The device's biggest advantage is providing such a recovery without the requirement for any surgical intervention and without being exposed to the side effects of drugs. I have been using tVNS device for over 2 years and will continue to use it." Barry Hanner. We are working for a better life...

The "tVNS Special Issue", has been published in the "Journal Autonomic Neuroscience", the official journal of the International Society for Autonomic Neuroscience, published by Elsevier. We are proud to design the future of neuroscience and to be the pioneer of the medical technologies. Below are the titles of the articles in the journal. Link is below: 1. tVNS in the treatment of drug-resistant epilepsy 2. Cardiovascular responses to low-level transcutaneous vagus nerve stimulation 3. Electrical vagus nerve stimulation as a prophylaxis for SIRS and postoperative ileus 4. tVNS as a potential therapeutic application for neurodegenerative disorders – A focus on dysautonomia in Parkinson's disease 5. tVNS in the management of headache and pain 6. Brain plasticity and vagus nerve stimulation 7. tVNS for the treatment of postural tachycardia syndrome 8. Functional anatomy of the vagus system – Emphasis on the somato-visceral interface 9. Effects of tVNS on cardiovascular autonomic control in health and disease 10. tVNS and heart rate variability: Analysis of parameters and targets 11. Current challenges in reliably targeting the noradrenergic locus coeruleus using transcutaneous auricular vagus nerve stimulation (taVNS) 12. The LC-NE system as a potential target for neuromodulation to ameliorate non-motor symptoms in Parkinson's disease 13. Vagus nerve afferent stimulation: Projection into the brain, reflexive physiological, perceptual, and behavioral responses, and clinical relevance 14. Transcutaneous vagus nerve stimulation (tVNS) in stroke: the evidence, challenges and future directions 15. t-VNS to treat disorders of behaviour in Prader-Willi Syndrome and in people with other neurodevelopmental conditions 16. Technical aspects and future approaches in transcutaneous vagus nerve stimulation (tVNS) 17. A two-week course of transcutaneous vagal nerve stimulation improves global sleep: Findings from a randomised trial in community-dwelling adults https://www.sciencedirect.com/journal/autonomic-neuroscience/special-issue/10DBND1B8HC

tVNS Nemos, that has improved the quality of life , in more than 3000 patients with epilepsy in the world since 2012, was has been applied to the first pediatric resistant epilepsy patient in Turkey last week. tVNS Nemos, which is the size of a mobile phone, stimulates the ear branch of the vagus nerve with the help of a special electrode headset, reduce the frequency and severity of epilepsy seizures by providing vagus nerve stimulation without the need for any invasive intervention and placement of a device in the body as a result of a total of 4 hours of sessions applied every day. As tVNS Turkey, we aim to reach patients who are suitable for tVNS vagus stimulation therapy and to increase the quality of life of our epilepsy patients.